Antimicrobial resistance (AMR) can arise when the organisms that cause an infection evolve ways to survive and render treatments ineffective, facilitating the infection’s spread. Global human consumption of antibiotics is expected to rise by more than 30% in the next 10 years, contributing to further rise and spread of ‘superbugs’ that cannot be treated with existing drugs1. Already, AMR is estimated to be the cause of at least 700,000 deaths globally each year, and this number is expected to rise to 10 million by 2050 if no action is taken2.
In addition to perceived potential new threats from emerging pathogens, vaccines are also focusing on bacterial infections for which antibiotic resistance is a growing challenge. Given that individuals are immunised before exposure it is unlikely that microbes, including bacteria, would develop resistance to vaccines. This is exemplified by the long-standing success of vaccination programmes against diphtheria, smallpox and other diseases.
We are working to deliver ImplaVax®-enabled vaccines to drive immunity against multiple pathogenic targets, when antibiotics typically target only one molecule in a bacterium. We believe this would further reduce the risk of resistance.
1. UK government (2019), UK 20-year vision for antimicrobial resistance
2. WHO (2019), New report calls for urgent action to avert antimicrobial resistance crisis
Enesi and an undisclosed partner are collaborating to develop a solid dose vaccine to fight Staphylococcal infection, a bacterial infection with rapidly increasing incidence, which shows resistance levels between 20% and 40% against methicillin.